Physician profile
William Abramovits
NPI 1154379188
$325,266.63
in general payments reported to CMS, 2019-2025
64 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $34K · 2021: $53K · 2022: $44K · 2023: $42K · 2024: $14K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $20K · Consulting Fee: $5,125 · Travel and Lodging: $3,860 · Education: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,543.00 |
| Food and Beverage | $19,624.56 |
| Consulting Fee | $5,125.00 |
| Travel and Lodging | $3,859.56 |
| Education | $538.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $67,385.75 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $55,363.76 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $30,685.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $30,398.87 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $24,714.38 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $23,314.38 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19,608.52 | 2019-2025 | Siliq, Arazlo, Duobrii |
| Celgene Corporation | $16,368.89 | 2019 | |
| Ucb, INC. | $9,846.24 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $8,852.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $7,507.19 | 2019-2025 | Sotyktu |
| Janssen Biotech, INC. | $6,368.29 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Epi Health, LLC | $5,459.07 | 2019-2022 | |
| Abbvie INC. | $3,268.77 | 2019-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $2,907.14 | 2019-2025 | Nemluvio, Aklief, Dysport |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,296.76 | 2025 | |
| Lilly USA, LLC | $2,279.68 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Incyte Corporation | $944.44 | 2021-2025 | Opzelura, Opzelura |
| Almirall LLC | $894.00 | 2019-2025 | Klisyri, Seysara |
| Arcutis Biotherapeutics, INC. | $866.62 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.39 | 2019-2025 | Spevigo |
| Boehringer Ingelheim International Gmbh | $671.50 | 2021 | |
| Promius Pharma LLC | $517.69 | 2019 | |
| Mayne Pharma Commercial LLC | $430.35 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $378.14 | 2019-2024 | Tremfya |
| Kyowa Kirin, INC. | $357.61 | 2022-2024 | Poteligeo |
| Dermavant Sciences, INC. | $309.85 | 2023 | Vtama |
| Journey Medical Corporation | $253.89 | 2019-2025 | |
| Botanix Sb INC | $247.13 | 2025 | Sofdra |
| Sandoz INC. | $238.84 | 2019-2024 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $234.41 | 2020 | |
| Allergan, INC. | $195.98 | 2021-2022 | |
| Genentech, INC. | $147.49 | 2025 | |
| Encore Dermatology INC. | $142.69 | 2019-2020 | |
| Organon LLC | $138.79 | 2025 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.57 | 2025 | Siliq |
| Sanofi US Services INC. | $116.15 | 2024-2025 | |
| Blueprint Medicines Corporation | $104.01 | 2025 | |
| Dermira, INC. | $73.72 | 2019-2021 | |
| Medimetriks Pharmaceuticals, INC. | $71.82 | 2019-2023 | Neo-Synalar |
| Biofrontera INC. | $65.32 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Krystal Biotech INC | $64.68 | 2025 | Vyjuvek |
| Janssen Pharmaceuticals, INC | $49.42 | 2023-2024 | Xarelto |
| Sebela Pharmaceuticals INC. | $48.69 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $33.37 | 2019 | |
| Phadia US INC. | $31.57 | 2021 | |
| Chiesi USA, INC. | $21.99 | 2024 | Filsuvez |
| Helsinn Therapeutics (U.S.), INC. | $20.55 | 2025 | Valchlor |
| Aclaris Therapeutics, INC. | $18.63 | 2019 | |
| Fidia Pharma USA INC. | $18.22 | 2025 | |
| Strata Skin Sciences, INC. | $11.16 | 2021 | |
| Kerecis Limited | $10.18 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,645.44 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Abramovits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.